Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial-Reference-Cited by-同舟云学术

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Published:2019-01-21 Issue:4 Volume:10 Page:1012-1021
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Inoue Hideka¹,Morino Katsutaro¹^ORCID,Ugi Satoshi¹,Tanaka‐Mizuno Sachiko²,Fuse Keiko¹,Miyazawa Itsuko¹,Kondo Keiko³,Sato Daisuke¹,Ohashi Natsuko¹,Ida Shogo¹,Sekine Osamu¹,Yoshimura Masahiro⁴,Murata Kiyoshi⁴,Miura Katsuyuki³,Arima Hisatomi⁵,Maegawa Hiroshi¹,

Affiliation:

1. Department of MedicineShiga University of Medical Science Otsu Shiga Japan

2. Department of Medical Statistics Shiga University of Medical Science Otsu Shiga Japan

3. Department of Public HealthShiga University of Medical Science Otsu Shiga Japan

4. Department of Radiology Shiga University of Medical Science Otsu ShigaJapan

5. Faculty of Medicine Department of Preventive Medicine and Public Health Fukuoka University Fukuoka Japan

Funder

Astellas Pharma

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.12985

Reference27 articles.

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

2. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

3. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

4. Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

5. Malnutrition-sarcopenia syndrome predicts mortality in hospitalized older patients

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Psoas Muscle Index in Middle-Aged Type 2 Diabetes Patients: Impact of Insulin Therapy on Sarcopenia;Tomography;2024-07-10

2. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

3. Unexpectedly Rapid Onset of Severe Sarcopenia in an Elderly Diabetic Man following SGLT2i Administration: A Case Report;Journal of Clinical Medicine;2024-05-11

4. Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2024-05-02

5. Exploring the Evolving Role of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Cardiovascular Injury Induced by Obesity: Spotlight on ROS as a Key Mediator;Oxidative Stress in Applied Basic Research and Clinical Practice;2024